Zotarolimus and Everolimus DES: Which Should You Choose?

Abstract

Aim: The optimal newer generation coronary drug eluting stent (DES) remains unknown. We compared clinical outcomes in patients treated with zotarolimus (ZDES) and everolimus eluting stents (EDES). Methods: The Melbourne Interventional Group (MIG) registry compared patients treated with ZDES (n = 1134) and EDES (n = 936) over a five-year period (2006-2011). Cohorts included only patients with de novo lesions stented exclusively with either DES type (excluding patients treated with additional bare metal stents). Results: The cohorts were matched for baseline demographics and lesion characteristics, except ZDES were used more frequently in ST- elevation myocardial infarction (17.9 vs. 13.6%, p = 0.03), smaller vessels (2.9 ± 1.0 vs.3.1 ± 1.0 mm, p < 0.01), and longer lesions (20.8 ± 9.3 vs. 19.6 ± 8.2 mm, p < 0.01). Clinical outcomes at 12 months are shown (Table).Tabled 1ZDES (n = 1134)EDES (n = 936)pDeath, n (%)35 (3.1)32 (3.4)0.67Myocardial infarction, n (%)69 (6.1)36 (3.8)0.02Target lesion revascularisation, n (%)41 (3.6)20 (2.1)0.05Target vessel revascularisation, n (%)75 (6.6)55 (5.9)0.49Stent thrombosis, n (%)34 (3.0)16 (1.7)0.06MACE, n (%)136 (12.0)101 (10.8)0.39 Open table in a new tab Conclusion: Patients with de novo lesions stented with ZDES have a higher incidence of myocardial infarction and target lesion revascularisation, yet were used in a higher risk cohort. An expanded cohort with complete late thrombosis rates will be available at presentation.Keywords: Drug Eluting Stent; Clinical Outcomes; MACE; Zotarolimus; Everolimus